79 related articles for article (PubMed ID: 17598653)
1. [Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia].
Broncel M; Balcerak M; Cieślak D; Duchnowicz P; Koter-Michalak M; Sikora J; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Feb; 22(128):107-11. PubMed ID: 17598653
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
3. [Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia].
Chi DS; Jin FX; Yang SG; Su YW; Ge B; Zhang J; Zhang Y; Liu YL
Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1109-11. PubMed ID: 12480587
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
6. [The erythrocyte membrane structure in patients with mixed hyperlipidemia].
Broncel M; Balcerak M; Bała A; Koter-Michalak M; Duchnowicz P; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(1-2):4-9. PubMed ID: 17607961
[TBL] [Abstract][Full Text] [Related]
7. [Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Broncel M; Chojnowska-Jezierska J; Koter-Michalak M; Franiak I
Pol Arch Med Wewn; 2005 Jun; 113(6):531-7. PubMed ID: 16454441
[TBL] [Abstract][Full Text] [Related]
8. [The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Broncel M; Koter-Michalak M; Chojnowska-Jezierska J
Przegl Lek; 2006; 63(9):738-42. PubMed ID: 17479860
[TBL] [Abstract][Full Text] [Related]
9. [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia].
Broncel M; Cieślak D; Koter-Michalak M; Duchnowicz P; Mackiewicz K; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2006 May; 20(119):547-50. PubMed ID: 16875159
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study).
Ilerigelen B; Uresin Y; San M; Kültürsay H; Güneri S; Serdar OA; Güleç S; Pençedemir H;
Curr Med Res Opin; 2007 May; 23(5):1093-102. PubMed ID: 17519076
[TBL] [Abstract][Full Text] [Related]
11. [The effect of early fluvastatin therapy on inflammatory factors in acute coronary syndrome].
Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM; Peng J
Zhonghua Nei Ke Za Zhi; 2005 Mar; 44(3):184-7. PubMed ID: 15840256
[TBL] [Abstract][Full Text] [Related]
12. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
13. [Effects of long acting fluvastatin on parameters of lipid metabolism in patients with type 2 diabetes and combined hyperlipidemia].
Kozlov SG; Liakishev AA; Titov VN; Naumov VG
Kardiologiia; 2004; 44(10):60-3. PubMed ID: 15477793
[No Abstract] [Full Text] [Related]
14. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
15. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM
Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
17. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure.
Di Lullo L; Addesse R; Comegna C; Firmi G; Galderisi C; Iannacci GR; Polito P
Adv Ther; 2005; 22(6):601-12. PubMed ID: 16510377
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration.
Scharnagl H; Vogel M; Abletshauser C; Freisinger F; Stojakovic T; März W
Cardiology; 2006; 106(4):241-8. PubMed ID: 16691029
[TBL] [Abstract][Full Text] [Related]
19. [The comparison in vitro the effects of pravastatin and quercetin on the selected structural parameters of membrane erythrocytes from patients with hypercholesterolemia].
Broncel M; Franiak I; Koter-Michalak M; Duchnowicz P; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Feb; 22(128):112-6. PubMed ID: 17598654
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
